{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 7,
  "pageCount": 58,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "industry_trends",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).",
  "elementsJson": [
    "headline_text",
    "bar_chart_vertical",
    "icon_grid",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/7",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-05829439d7c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials in China (2016-21)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b40ee35b-8ba6-4159-bc5a-f8c47135bc85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.04,
        "y": 0.54
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials in U.S. (2016-21)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e11bd5d4-791a-47fa-8803-0d712376ef52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "list",
      "text": "Key drivers: Favorable policy, Accelerated innovative drug development, Continuous R&D investment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9245a129-739d-4459-89ca-57e24b3c038a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "CAGR: 29%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-09ee9369c7ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Source: DXY, Trialtrove, L.E.K. research and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c7b6f2a-74ab-4468-9236-9f6ff04d84d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c078b04-ff60-407b-aa0d-dc872000e1fd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "CAGR",
      "numberRaw": "29%",
      "numberKind": "percent",
      "actionTitle": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment",
      "calloutText": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment.",
      "numberScale": null,
      "numberValue": 29,
      "metricFamily": "growth_rate",
      "numberCurrency": null
    }
  ],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "88d8805a-9b08-431b-8523-9594c15adf24",
      "evidence": "chart/bar-vertical: Number of newly started clinical trials in China (2016-21)",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d87fad6b-0c9b-45b6-bf4c-46a182e83faa",
      "evidence": "list/bullet: Key drivers: Favorable policy, Accelerated innovative drug development, Continuous R&D investment",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "2e308d53-f564-4d1b-a207-755a279e3246",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}